ANRO Stock Summary and Trading Ideas (Alto Neuroscience | NYSE:ANRO)

Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience trades on the NYSE stock market under the symbol ANRO.

As of June 18, 2025, ANRO stock price climbed to $2.27 with 147,858 million shares trading.

ANRO has a beta of 2.20, meaning it tends to be more sensitive to market movements. ANRO has a correlation of 0.07 to the broad based SPY ETF.

ANRO has a market cap of $61.45 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that ANRO belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWO.

ANRO has underperformed the market in the last year with a price return of -79.6% while the SPY ETF gained +10.2%. ANRO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -21.2% and -7.3%, respectively, while the SPY returned +6.8% and +0.3%, respectively.

ANRO support price is $2.12 and resistance is $2.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANRO shares will trade within this expected range on the day.